Enveric Biosciences, Inc. (ENVB): restructuring charge — Enveric Biosciences cuts 50% of workforce (7 positions) to reduce costs

Enveric Biosciences, Inc.

Approximately 7 positions eliminated, representing ~50% of global workforce, to streamline operations.
Estimated severance and transition costs of ~$40,000, to be recognized in Q1 2024.
RIF expected to be substantially complete by February 15, 2024.
Company cites cost reduction and organizational streamlining as reasons for the action.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.99

Enveric Biosciences, Inc. announced a restructuring with charges of approximately $40,000 (approximately seven positions, representing approximately 50% of the Company's global workforce).

Type: restructuring
Charge: approximately $40,000
Headcount: approximately seven positions, representing approximately 50% of the Company's global workforce

Exact text from the filing

to decrease its costs and create a more streamlined organization to support its business. In connection with the RIF, the Company currently estimates it will incur approximately $40,000 of costs, consisting primarily of cash severance costs and transition support services for impacted employees, which the Company expects to recognize in the first quarter of 2024.

View on SEC.gov

2 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-001717

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.